Vnitr Lek 2013, 59(7):627-630

Multiple myeloma

I. Špička^*, M. Klánová

I. interní klinika - klinika hematologie 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Marek Trněný, CSc.

Multiple myeloma is one of the most common hematological malignancies with increasing prevalence. Not until the introduction of 1 or 2 cycles of high-dose therapy with the support of hematopoietic cells meant a certain progress in the prognosis of patients. The radical change in the therapy efficiency was not made possible until the so-called new or targeting drugs - thalidomide, bortezomib and lenalidomide. The 2 latter preparations have particularly changed the approach to the disease itself from one of the least prognostically favourable hematological tumours to a long-term controllable malignancy with a potential to treat at least some of the patients. Currently, 3 ways of further progress towards more efficient treatment methods are under investigation: a) maintenance or consolidation treatment aimed at further intensification of therapeutic response, b) combination of targeting drugs and c) efficiency of the "second generation" targeting drugs.

Keywords: multiple myeloma; bortezomib; lenalidomide; carfilzomib

Received: April 23, 2013; Published: July 1, 2013  Show citation